Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Poor prognosis linked to BRCA1 mutations

24.10.2003


Breast cancer patients have a lower chance of long-term survival if they carry an inherited mutation in the BRCA1 gene, according to research published in Breast Cancer Research this week. However, the poor prognosis associated with the mutated gene is mitigated by chemotherapy.



The breast cancer susceptibility genes, BRCA1 and BRCA2, were identified over eight years ago, but the best way of treating women who develop hereditary breast cancer associated with mutations in these genes is still not clear.

A team of researchers from McGill University in Montreal and the Memorial Sloan-Kettering Cancer Center in New York investigated how the prognosis of breast cancer was affected by mutations in BRCA1 and BRCA2, and by the administration of chemotherapy. They studied the clinical records of 496 women of Ashkenazi Jewish descent who underwent treatment for invasive breast cancer between 1980 and 1995. Their results suggest that physicians should take the presence of such mutations into account when they are making treatment decisions.


56 of the women studied carried at least one mutation in either the BRCA1 or the BRCA2 gene. 79 of the women died from their breast cancer within ten years of diagnosis.

The ten-year survival rates for women with BRCA1 mutations were worse than those without mutations (38% of carriers died compared with 14% of non-carriers). However, the presence of a BRCA1 mutation did not reduce long-term survival if the women were treated with chemotherapy. Risk factors other than the mutations are likely to cause a poor prognosis under these circumstances.

The ten-year survival rates for women with BRCA2 mutations did not differ to those of non-carriers. Also, administration of chemotherapy did not affect survival rates of women with BRCA2 mutations, but the authors acknowledge that the sample size is too small for definitive conclusions

Further studies are necessary to see if the type of chemotherapy used has an effect when these mutations are present.

The researchers say: "This study demonstrates that women with specific BRCA1/2 mutations who develop breast cancer are at increased risk from death from their disease, particularly if the mutation is in BRCA1."

Although other factors contributed to a poor prognosis, for example if breast cancer was first diagnosed when the women were under 50 years old or if the tumour was larger than 2cm upon diagnosis, mutations in BRCA1 predicted an increase in mortality even when these factors were taken into account (if chemotherapy was not given). It may be that chemotherapy is particularly effective for women who carry a BRCA1 mutation.

The risk for breast cancer in the unaffected breast was much higher for BRCA1/2 mutation carriers than non-carriers. However, the 10-year risk of cancer returning in the treated breast was no greater in women with the BRCA mutations than in women without. This may have implications for women who have to choose between bilateral mastectomy and breast conservation, however, a longer follow-up study is needed before women can be reliably advised.

For further information about this research, please contact Associate Professor William Foulkes by email at William.foulkes@mcgill.ca or by phone on 514-934-1934 x44121

Gemma Bradley | EurekAlert!
Further information:
http://breast-cancer-research.com/content/6/1/R8

More articles from Life Sciences:

nachricht New photocatalyst speeds up the conversion of carbon dioxide into chemical resources
29.05.2017 | DGIST (Daegu Gyeongbuk Institute of Science and Technology)

nachricht Copper hydroxide nanoparticles provide protection against toxic oxygen radicals in cigarette smoke
29.05.2017 | Johannes Gutenberg-Universität Mainz

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Strathclyde-led research develops world's highest gain high-power laser amplifier

The world's highest gain high power laser amplifier - by many orders of magnitude - has been developed in research led at the University of Strathclyde.

The researchers demonstrated the feasibility of using plasma to amplify short laser pulses of picojoule-level energy up to 100 millijoules, which is a 'gain'...

Im Focus: Can the immune system be boosted against Staphylococcus aureus by delivery of messenger RNA?

Staphylococcus aureus is a feared pathogen (MRSA, multi-resistant S. aureus) due to frequent resistances against many antibiotics, especially in hospital infections. Researchers at the Paul-Ehrlich-Institut have identified immunological processes that prevent a successful immune response directed against the pathogenic agent. The delivery of bacterial proteins with RNA adjuvant or messenger RNA (mRNA) into immune cells allows the re-direction of the immune response towards an active defense against S. aureus. This could be of significant importance for the development of an effective vaccine. PLOS Pathogens has published these research results online on 25 May 2017.

Staphylococcus aureus (S. aureus) is a bacterium that colonizes by far more than half of the skin and the mucosa of adults, usually without causing infections....

Im Focus: A quantum walk of photons

Physicists from the University of Würzburg are capable of generating identical looking single light particles at the push of a button. Two new studies now demonstrate the potential this method holds.

The quantum computer has fuelled the imagination of scientists for decades: It is based on fundamentally different phenomena than a conventional computer....

Im Focus: Turmoil in sluggish electrons’ existence

An international team of physicists has monitored the scattering behaviour of electrons in a non-conducting material in real-time. Their insights could be beneficial for radiotherapy.

We can refer to electrons in non-conducting materials as ‘sluggish’. Typically, they remain fixed in a location, deep inside an atomic composite. It is hence...

Im Focus: Wafer-thin Magnetic Materials Developed for Future Quantum Technologies

Two-dimensional magnetic structures are regarded as a promising material for new types of data storage, since the magnetic properties of individual molecular building blocks can be investigated and modified. For the first time, researchers have now produced a wafer-thin ferrimagnet, in which molecules with different magnetic centers arrange themselves on a gold surface to form a checkerboard pattern. Scientists at the Swiss Nanoscience Institute at the University of Basel and the Paul Scherrer Institute published their findings in the journal Nature Communications.

Ferrimagnets are composed of two centers which are magnetized at different strengths and point in opposing directions. Two-dimensional, quasi-flat ferrimagnets...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Marine Conservation: IASS Contributes to UN Ocean Conference in New York on 5-9 June

24.05.2017 | Event News

AWK Aachen Machine Tool Colloquium 2017: Internet of Production for Agile Enterprises

23.05.2017 | Event News

Dortmund MST Conference presents Individualized Healthcare Solutions with micro and nanotechnology

22.05.2017 | Event News

 
Latest News

New insights into the ancestors of all complex life

29.05.2017 | Earth Sciences

New photocatalyst speeds up the conversion of carbon dioxide into chemical resources

29.05.2017 | Life Sciences

NASA's SDO sees partial eclipse in space

29.05.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>